Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the optimal amount of Propylene Glycol in Minoxidil for better absorption. It focuses on enhancing the effectiveness of Minoxidil in treating hair loss.

OP is seeking recommendations for thickening tonics and decides to try Aveda thickening tonic after a suggestion. Another user recommends hair powder as an alternative.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.

Enhancing minoxidil effects can involve using penetration enhancers like DMSO, urea, or retinol, and methods like dermarolling and adding substances like biotin and L-carnitine tartrate. Some users suggest trying higher concentrations of minoxidil if lower percentages are ineffective.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

A user noticed a color change in their hair loss solution containing minoxidil, finasteride, retinoic acid, and hydrocortisone after storing it for several months. They are concerned about the effectiveness of the solution due to potential oxidation.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

The conversation discusses making topical finasteride at home, questioning the necessity of removing the pill's coating before use. Users suggest that the coating isn't harmful, and finasteride dissolves in ethanol, with some recommending filtering out the coating and fillers.

The conversation discusses using propanediol as an alternative to glycerin in PG-free minoxidil for better absorption. The user also plans to try nanoxidil, which may absorb more easily due to its smaller molecule size.

User can't find 2% keto shampoo in their area and asks about ketoconazole BP20. Replies confirm that 20mg/ml means 2% ketoconazole and BP stands for British Pharmacopoeia, ensuring purity and quality standards.

AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.

Mixing dutasteride capsules and tretinoin cream into liquid minoxidil is questioned for effectiveness. A user responds negatively.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

The conversation is about whether castor oil can be effectively used alone after microneedling without a penetration enhancer like DMSO or ethanol. The user believes microneedling-induced wounds might be enough for absorption.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

People are discussing making their own PP405 for hair loss treatment using JLX069 and DMSO. There is skepticism about the safety and effectiveness of this homemade solution, with some users expressing concerns about potential risks.

Hair loss discussion includes PRP and exosomes treatments. Questioning effectiveness and ideal candidate for these treatments.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

A 32-year-old male with diffuse thinning and seborrheic dermatitis has been using finasteride for 8 months without improvement. He is considering COQ10 + PQQ supplements for scalp inflammation and hair loss.

Minoxidil, dutasteride, and copper peptides are used in a tattooing method for hair regrowth, with some users noting better results compared to oral treatments. Copper peptides are considered to have minimal impact, but the method may reduce side effects.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.